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ABSTRACT 
Background and purpose: Immune checkpoint inhibitor with radiation therapy (ICI + RT) is 
under investigation for improved patient outcome, so we performed a systematic review/meta-
analysis of toxicities for ICI + RT compared to immune checkpoint inhibitor (ICI) therapy alone. 
Materials and methods: A PRISMA-compliant systematic review of studies in MEDLINE 
(PubMed) and in the National Comprehensive Cancer Network guidelines was conducted, with 
primary outcome grade 3+ toxicity. Criteria for ICI alone were: phase III/IV trials that compared 
immunotherapy to placebo, chemotherapy, or alternative immunotherapy; and for ICI + RT: 
prospective/retrospective studies with an arm treated with ICI + RT. Meta-analysis was 
performed by random effects models using the DerSimonian and Laird method. The I2 statistic 
and Cochran’s Q test were used to assess heterogeneity, while funnel plots and Egger’s test 
assessed publication bias. 
Results: This meta-analysis included 51 studies (n=15,398), with 35 ICI alone (n=13,956) and 
16 ICI + RT studies (n=1,442). Our models showed comparable grade 3-4 toxicities in ICI + RT 
(17.8%; 95% CI, 12.0-24.5%) and ICI alone (22.3%; 95% CI, 18.1-26.9%). Stratification by 
timing of radiation and irradiated site showed no significant differences, but anti-CTLA4 therapy 
and melanoma showed increased toxicity. The grade 5 toxicities were 1.1% and 1.9% for ICI 
alone and ICI + RT respectively. There was significant heterogeneity, but not publication bias. 
Conclusions: The random effects model showed comparable grade 3-4 toxicity in using ICI + 
RT compared to ICI alone in CNS melanoma metastases, NSCLC, and prostate cancer. ICI + RT 
is safe for future clinical trials in these cancers. 
Keywords: combination therapy, radiation, immune checkpoint inhibitor, toxicity  
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INTRODUCTION 
Recent rising use of immune checkpoint inhibitors (ICIs) in metastatic and recurrent cancers 
leverages their systemic activity to eradicate disseminated malignancies. For example, the 
current National Comprehensive Cancer Network (NCCN) guidelines (version 1.2019) for newly 
diagnosed metastatic melanoma to the brain recommend four treatment options: ipilimumab with 
nivolumab, nivolumab alone, pembrolizumab, or BRAF/MEK inhibitors.1 Similarly, radiation 
therapy (RT) may be used for palliation or definitive treatment of oligoprogressive disease.1 
However, ICI use results in well-characterized accompanying toxicities.2 Targets of ICI therapy 
include cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death protein 1 (PD1), and 
programmed death-ligand 1 receptor (PDL1).3 
 There is interest in combining ICI with RT in order to increase efficacy of therapy and 
reduce rate of recurrence,4-21 as well as to explore the possibility of enhancing an abscopal effect. 
However, there are few data regarding the toxicity of this combination therapy in humans. The 
proinflammatory effects of ICI and RT may be additive, resulting in unacceptable toxicity. A 
recent meta-analysis found that in patients treated for brain metastases by ICI and SRS, 
ipilimumab was associated with greater risk of radionecrosis.7, 22, 23 There is evidence that PD-1 
signaling is significantly involved in radiation-induced cardiac toxicity.24 Finally, it is not known 
what timeline of ICI and RT maximizes efficacy without sacrificing safety, though some 
evidence suggests concurrent therapy is superior to non-concurrent.6, 25, 26  
 There are currently limited data available across disease sites regarding the safety of 
combination ICI + RT, with respect to ICI target, RT fractionation, timing of therapy, and region 
irradiated. We sought to compare toxicity of ICI + RT to ICI alone, review evidence for 
differences in timing of ICI + RT administration, and to examine other factors which may affect 
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toxicity. We hypothesized there is no increase in toxicity due to ICI + RT therapy compared to 
ICI alone.  
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MATERIALS AND METHODS 
Evidence acquisition 
The inclusion criteria for the literature search was defined using the Population, 
Intervention, Control, Outcome, Study Design (PICOS), per Table 1.27-29 The Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) literature selection 
protocol was used for article selection, per Figure 1.30 The Meta-analyses Of Observational 
Studies in Epidemiology (MOOSE) guidelines were followed.  
Medical literature including clinical trials, clinical studies, comparative studies, and 
multicenter studies published in English was searched in PubMed, Google Scholar, and the 2019 
NCCN guidelines. For ICI alone, the search terms used were: (nivolumab or ipilimumab or 
pembrolizumab or durvalumab or cemiplimab or atezolizumab or avelumab or tremelimumab or 
ctla4 or pd1 or pdl1). For ICI + RT, the search terms used were the same along with: and 
("radiation therapy" or radiotherapy or radiosurgery); the ICI alone results were limited to phase 
III/IV clinical trials in humans. 703 ICI + RT studies and 93 ICI alone studies from PubMed 
were found and screened based on title to exclude non-relevant studies such as basic science and 
non-human studies; 12 additional non-duplicate ICI + RT records were identified from the 
NCCN guidelines. The studies were checked for completeness by coauthors who are both 
medical and radiation oncologists (EL, NZ, DT, CH). Of the 618 ICI + RT and 93 ICI alone non-
duplicate remaining studies, 29 ICI + RT and 66 ICI alone full-text articles passing the title 
screening were reviewed for inclusion of relevant treatment and toxicity data. An additional 13 
ICI + RT articles were excluded for not including grade 3-4 adverse event data, and 27 ICI alone 
articles excluded as subgroup analyses of trials already included (Figure 1). 
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Data extraction 
51 full-text articles (16 ICI + RT and 35 ICI alone) were reviewed and coded into a 
database by two authors (CMS and EL); discrepancies were discussed with three other authors 
(NZ, DT, CH). Extracted data included number of patients, disease site, therapy (radiation 
method and/or ICI used), timing of radiation with respect to immunotherapy, radiation dose and 
fractionation, radionecrosis incidence, and toxicities (grade 3-4 and/or grade 5). Each study arm 
was coded separately, and RT alone control arms in the ICI + RT studies were excluded. 
Intervention and endpoints 
The intervention was radiation therapy alone (RT), immunotherapy alone (ICI), or 
combination radiation and immunotherapy (ICI + RT). Included ICI + RT studies could have 
multiple arms comparing therapies or could be single-arm studies of each intervention alone.  
 The primary endpoint was worst reported grade 3-4 toxicities for each patient. One study 
did not provide this information, and we reached out to the corresponding author for patient 
adverse event logs.11 In this case, we coded a grade 3-4 toxicity if the toxicity was “probably” or 
“definitely” caused by treatment. 
We classified timing RT relative to ICI administration into four categories: “before” in 
which RT was given and completed before an ICI; “mixed” in which RT was given before the 
ICI and continued during ICI administration; “concurrent” in which RT was administered within 
4 weeks after ICI; and “after” in which RT was administered past 8 weeks after the last ICI. We 
provide this timing data in Supplemental Table 3. Data were discussed by all authors to 
maintain reporting accuracy. 
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Statistical Analysis 
RStudio version 3.6.1 (Boston, MA) and The Meta-Analysis Package for R (metafor v. 
2.1.0) version were used to conduct the meta-analyses.31, 32 The General Package for Meta-
Analysis was used to generate the forest plots. The DerSimonian and Laird method was used to 
perform meta-analysis of grade 3-4 toxicities.33 Univariate meta-regression of toxicities was also 
performed with respect to concurrency of ICI + RT, RT target, immune signaling axis targeted 
by ICI, malignant histology, and ICI used. Heterogeneity was assessed using the I2 statistic and 
the Cochran Q-Test, with significance if I2>50% and p<0.10 respectively.34 
Random effects models were used over fixed effects models to mitigate heterogeneity. 
Forest plots were generated for ICI alone and ICI + RT. Graphing of meta-regression intercepts, 
95% confidence intervals, and statistical significance by Wald test were also performed. A 
Bonferroni correction was applied to the p-values of the Wald-type tests for each categorical 
variable, so that the null hypothesis was rejected with p<0.05. 
We analyzed the studies for publication bias using funnel plots (funnelR) and tested for 
asymmetry with Egger’s test, significant if p<0.05.35  
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RESULTS 
The meta-analysis included 15,398 patients across 51 studies published during the years 
2004-2019.4-7, 9-12, 14-16, 18, 20, 21, 36-71 The ICI + RT studies were mainly from the United States, 
with two studies done in France,7, 12 one study in Italy,15 one in Australia,18 and one between 
Belgium and Canada.21 The ICI alone studies included multi-national/multi-center randomized 
clinical trials with patients from the United States, the United Kingdom, France, Spain, Poland, 
Denmark, Germany, Hungary, Austria, Canada, Australia, and other countries. 
 There were 35 studies with ICI alone arms totaling 13,956 patients (Supplemental Table 
3).36-71 Disease sites include cancers of head and neck,41, 42 stomach,49, 68 melanoma,46, 47, 50, 51, 56, 
58, 59, 61, 62, 67, 70, 71 lung,38-40, 43-45, 55, 57, 60, 63, 64, 69 kidney,12, 53, 54, 65 prostate,36 and urothelial 
origin.37, 52, 66 Four studies compared ICI alone regimens to other ICI alone regimens.58, 63, 70, 71 
Three studies assigned multiple ICI therapy to an arm (combination nivolumab with 
ipilimumab).63, 65, 71 The ICIs used were: anti-CTLA4 (ipilimumab36, 46, 47, 58, 59, 61, 63, 65, 70, 71), anti-
PD1 (nivolumab,38-40, 42, 44, 51, 54, 63, 65, 67, 69-71 pembrolizumab37, 41, 43, 45, 50, 55, 58, 62, 64, 68), and anti-
PDL1 (atezolizumab,53, 57, 66 avelumab,60 durvalumab52). 
 There were 16 studies with ICI + RT arms totaling 1,442 patients (Supplemental Table 
3).4-7, 9, 11-21 Of these, 507 patients were given concurrent RT and ICI,7, 13, 16 456 were given RT 
courses ending before ICI administration,9, 17, 20 and the remaining 479 patients were give a 
combination of timings of RT with respect to ICI administration.4-6, 11, 12, 14, 15, 18, 19, 21 Most 
studies reported a disease site of melanoma metastases to the brain;4-6, 9, 11, 12, 14, 16, 18, 19 other 
disease sites included cancers of lung,5, 13-15 kidney,5, 14, 15, 19 prostate,17, 20 and urothelial origin.21 
The ICIs used were: anti-CTLA4 (ipilimumab5, 6, 11, 16, 17, 19, 20, tremelimumab56), anti-PD1 
(nivolumab,5, 12, 15, 18, 19 pembrolizumab4, 5, 12, 18, 21), and anti-PDL1 (durvalumab7, 13). Median 
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radiation dosage for all ICI + RT patients was 22.5 Gy / 1 fraction. One study included 473 
patients who received 60 Gy in multiple fractions to the lungs,13 and two other studies totaling 
434 patients delivered 8 Gy / 1 fraction to bony lesions from the prostate.17, 20, 31 
 We assessed for publication bias using funnel plots and Egger’s test (Supplemental 
Figure 1). For ICI alone, Egger’s test gave p=0.698 while for ICI + RT, Egger’s test gave 
p=0.258. Since p>0.05 in both cases, we did not reject the null hypothesis that the funnel plots 
are symmetric. 
 According to our weighted random effects model, worst reported grade 3-4 toxicities are 
observed in 22.3% (95% confidence interval: 18.1-26.9%) of ICI alone patients and 17.8% (95% 
CI: 12.0-24.5%) of ICI + RT patients. Forest plots are in Figures 2A and 2B, with side-by-side 
comparison in Figure 2C. 
Across all ICI + RT studies, only 2 patients in one multi-arm study and 1 patient in a case 
series were reported to experience grade 3-4 radionecrosis.5, 18 The authors did not find 
significant differences in radionecrosis among the RT, concurrent ICI + RT, or non-concurrent 
ICI + RT groups.6 
From univariate categorical meta-regression, no statistically significant differences in 
grade 3-4 toxicity were seen in either the timing or irradiated site for the ICI + RT studies 
(Figures 3A and 3B). Variables which resulted in significant differences in grade 3-4 toxicity 
were: the axis targeted (e.g. anti-PD1 vs anti-CTLA4, Figure 3C), the histological origin of the 
malignancy (e.g. HNSCC vs melanoma, Figure 3D), and the specific ICI used in the study (e.g. 
durvalumab vs ipilimumab, Figure 3E).  
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A statistically significant effect on grade 3-4 toxicity was seen with histological origin of 
the malignancy in the ICI alone studies (Figure 3D). Treatment of melanoma was associated 
with greater toxicity than treatment of NSCLC. However, this result may be confounded by the 
effects of anti-CTLA4 therapy, with 9 melanoma arms out of 19 total treated with ipilimumab;46, 
47, 58, 59, 61, 70, 71 one additional arm was treated with the anti-CTLA4 agent tremelimumab.56 No 
such effect was seen for the ICI + RT studies. 
Anti-CTLA4 therapy increased grade 3-4 toxicity compared to anti-PD1 therapy and anti-
PDL1 therapy in the ICI alone studies (Figure 3C). The breakdown of specific ICIs reflects this 
trend in the ICI alone studies, with the anti-CTLA4 ipilimumab and tremelimumab showing 
increased toxicity compared to the anti-PD1 nivolumab and pembrolizumab and the anti-PDL1 
atezolizumab and durvalumab (Figure 3E).  
 There were twenty-eight grade 5 toxicities (deaths related to treatment) observed in the 
phase III ICI + RT studies. Grade 5 toxicities were observed at a rate of 4.4% (21 deaths) for 
non-small cell lung cancer (NSCLC treated with adjuvant durvalumab and definitive platinum-
based chemoradiotherapy,13 and 1.0% (7 deaths) for castration-resistant prostate cancer treated 
with concurrent ipilimumab and directed radiotherapy for bone metastases.17 No other ICI + RT 
study included in this meta-analysis reported any grade 5 toxicities, giving an overall grade 5 
toxicity incidence of 1.9% (28 deaths out of 1,442 treated) for the ICI + RT studies. This rate 
was similar to the overall grade 5 toxicity incidence of the ICI alone studies, which was 1.1% 
(158 deaths out of 13,956 treated).36-47, 49-71  
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DISCUSSION 
ICI + RT is currently being investigated as a treatment strategy for cancers of various 
origin, however there are few clinical trials with characterize the toxicity of ICI + RT compared 
to ICI alone. This meta-analysis indicates that around 1 in 5 patients treated with ICIs 
experienced treatment-related grade 3-4 toxicity, a rate paralleled in ICI + RT patients regardless 
of timing of ICI + RT administration. Incidence of treatment-related grade 5 toxicity was slightly 
higher for ICI + RT than for ICI alone, at 1.9% and 1.1% respectively. Due to the similar 
toxicities between ICI + RT and ICI alone, it appears that ICI + RT is a viable treatment option 
and warrants further study. 
In the ICI alone studies, the significant heterogeneity observed may be due to differences 
in adverse event grading, ICI agent used, and disease site. There were some study arms with 
significantly higher rates of grade 3-4 toxicity.12, 46, 47, 61, 65, 70, 71 The disease sites (i.e. melanoma, 
renal cell carcinoma) and ICI agents used (i.e. ipilimumab, tremelimumab, nivolumab) in these 
studies are similar to other studies with far lower grade 3-4 toxicity. The study by Ribas et al. 
reported all grade 3-4 toxicities and not treatment-related grade 3-4 toxicities.56 One study by 
Hodi et al. from 2014 did have high treatment-related grade 3-4 toxicities.47 Trials involving 
combination nivolumab with concurrent ipilimumab showed high toxicity,63, 65, 71 a result 
confirmed in Figure 3E, where nivolumab + ipilimumab shows significant increase in toxicity 
compared to all other ICIs except ipilimumab and tremelimumab alone. 
The ICI + RT studies showed high heterogeneity and a smaller sample size than the ICI 
alone studies. Our meta-regression showed no differences in grade 3-4 toxicities with respect to 
timing of ICI + RT administration or the irradiated site (Figures 3A and 3B). There was an 
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outlier for ICI + RT grade 3-4 toxicity at 68.2%, 2-3 times as high as similar studies with anti-
CTLA4 + RT treatment.9 
The trend toward targeted immune checkpoint inhibitors has significantly improved 
outcomes in malignancies once solely treated by radiation therapy or chemotherapy, with fewer 
severe side effects than chemotherapy.3 By blocking anti-inflammatory signals from malignant 
cells, ICIs increase helper and CD8+ T cell activation, allowing for recognition and destruction 
of malignant cells.72 At the same time, ICIs are systemic agents and the haphazard activation of 
immune cells throughout the body by ICIs explains their toxicities. This may even be a target for 
personalized medicine, as some patients may be predisposed to certain toxicities.73  
 There are several proposed mechanisms by which combination ICI + RT therapy can 
enhance the activity of the ICI resulting in a synergistic effect. In addition to RT causing 
radiation-induced damage to malignant cell DNA and other cellular components, the resultant 
clearance of damaged tumor cells by antigen-presenting cells (APCs) increases subsequent 
activation of T cells by APCs, facilitated by disruption of inhibitory CTLA4 and PDL/PDL1 
signals.10 For instance, stereotactic radiosurgery (SRS) is theorized to sensitize CD8+ T cells to 
tumor-specific antigens, and thus act as an in vivo “vaccine.”72 An immune response can 
sometimes be induced systemically, leading to the so-called abscopal effect.22 We may also ask 
if there is an “abscopal toxicity” due to sensitization of CD8+ T cells to self-antigens; this would 
be one possible way RT could enhance ICI toxicity.74 As subjective and clinician-dependent as 
toxicity grading already is, singling out toxicities caused by the combination of ICI + RT may be 
infeasible. 
Hypofractionated or ablative RT are being investigated for increased pro-immunogenic 
properties and enhancing the abscopal effect, however there may be risks for increased toxicity 
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as discussed above. There are several case reports of an abscopal effect when ICI is combined 
with RT in the human and animal models.24, 75, 76 There are also preclinical studies which show 
that conventional RT may have anti-immunogenic properties through induction of regulatory T 
cells, so further investigation of the fractionation of RT is needed to explore its effect on the 
immune response.77 Unfortunately, we were unable to evaluate the effect of various fractionation 
schemes as we did not have patient-level data. There is evidence that fractionation plays a role in 
toxicity, however this conclusion was made for cetuximab + RT and not ICI + RT.78 This 
highlights the need for high quality randomized controlled trials with various fractionations of 
RT in ICI + RT to further investigate the effect of fractionation on toxicities. 
 There were numerous other limitations to our studies. There was high heterogeneity in 
the studies included in our meta-analysis. However, our aim was to assess all possible toxicity 
from all permutations of combination ICI + RT, so this heterogeneity is expected. We addressed 
the heterogeneity by using a random effects model over a fixed effects model. There were no 
individual patient-level data. Many of the studies of ICI + RT treatment were primarily 
concerned with melanoma metastases to the brain, whereas the ICI alone data pooled results 
from a variety of cancer sites, thus we are unable to confidently generalize our ICI + RT results 
to other cancers and ICI + RT regimens. Another possible source of bias in our analysis could be 
under-reporting of toxicity in retrospective compared to prospective studies. We also were not 
able to control for the effect of ICI agent or dosage, and this may have affected the toxicities of 
experimental treatments such as the nivolumab + ipilimumab trials,65, 71 or trials which focused 
on effects of ICI dosing.59 Some of the differences we observed (e.g. higher rates of toxicity in 
melanoma vs NSCLC trials) may be related to the greater use of CTLA4-targeted therapy in 
melanoma trials. There were almost ten times as many patients in the ICI alone studies (13,956) 
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as in the ICI + RT studies (1,442). We thus may not have had sufficient statistical power to 
distinguish effects of various factors on ICI + RT toxicity. Clinicians await the results of clinical 
trials such as NCT03601455 (durvalumab/tremelimumab with RT) and NCT03604991 
(nivolumab/ipilimumab with RT). 
Based on our random effects models, adding RT to ICI therapy does not increase 
incidence of grade 3-4 toxicities and the combination treatment is safe for use across a variety of 
ICI agents and for CNS melanoma metastases, NSCLC, and prostate cancer. The safety of 
concurrent administration of ICI + RT is of interest, as there is preliminary clinical evidence that 
concurrent administration improves overall survival over non-concurrent ICI + RT. For patients 
receiving an ICI, anti-CTLA4 agents such as ipilimumab and tremelimumab are associated with 
worse grade 3-4 toxicities. Existing data and this analysis support combining ICI and SRS in 
certain patient populations. Due to the hypothesis-generating nature of this study, further 
prospective studies are needed to validate this treatment combination.  
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FIGURE CAPTIONS 
Figure 1: PRISMA flow diagram 
Figure 2: Forest plots and summary 
A. The grade 3-4 toxicities for ICI therapy alone, with 95% confidence intervals. Each row 
represents a different prospective clinical trial which used an ICI (Therapy) for a 
malignancy (Histology). An overall random effects estimate is provided in bold. Test 
statistics are shown on the bottom left. Our meta-analysis shows 22.3% (95% CI: 18.1-
26.9%) of patients receiving ICI alone experience grade 3-4 toxicities. Note the high 
heterogeneity present, with I2=97% and Cochran’s Q-test showing significance at the p < 
0.01 level. 
B. The grade 3-4 toxicities for ICI + RT, with 95% confidence intervals. Each row 
represents an arm of a given study which used an ICI (Therapy) for a malignancy 
(Histology) as well as radiation (Irradiated Sites) with varying timing of ICI 
administration with respect to radiation (Timing). An overall random effects estimate is 
provided in bold. Test statistics are shown on the bottom left. Our meta-analysis shows 
16.3% (11.1-22.3%) of patients receiving ICI + RT experience grade 3-4 toxicities. High 
heterogeneity is also present here, with I2=84% and Cohcran’s Q-test showing 
significance at the p < 0.01 level. 
C. 95% confidence intervals for grade 3-4 toxicities for ICI alone and ICI + RT (blue). ICI + 
RT is further stratified by concurrency of ICI and RT administration (orange). I2, χ are 
shown, with * indicating significant heterogeneity (p<0.05). Full numerical values with 
summary of data are shown in Supplemental Table 1. Note that the 95% confidence 
interval of ICI + RT grade 3-4 toxicities lies well within that of the ICI alone estimates. 
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Figure 3: Stratification by factors 
Blue bars indicate ICI + RT while orange bars indicate ICI alone. * indicates statistical 
significance to the level of α < 0.05. Full data are shown in Supplemental Table 2. We show the 
meta-regression estimates of grade 3-4 toxicities with errorbars showing 95% confidence 
intervals) stratified by: 
A. timing of RT with respect to ICI administration. All the 95% confidence intervals overlap 
and there were no significant differences. 
B. site which was irradiated. This variable was coded with a focus on radiation directed at 
the brain and radiation directed elsewhere. All the 95% confidence intervals overlap and 
there were no significant differences. 
C. immune signaling axis targeted by the ICI used. There are significant differences in the 
ICI alone groups (α<0.05), with treatments including anti-CTLA4 therapy causing 
increased toxicity compared to treatments without anti-CTLA4 therapy. 
D. histologically determined origin of the malignancy. There are no significant differences 
except for between NSCLC and melanoma (α<0.05). Histology does not appear to play a 
significant role in toxicity experienced. 
E. the specific ICI agent(s) used. There are significant differences between therapies that 
contain anti-CTLA4 agents (i.e. ipilimumab, tremelimumab) compared to those that do 
not (α<0.05).  
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Table 1: PICOS 
ICI alone 
Population Cancer patients undergoing treatment of cancer by ICI 
Intervention Any ICI 
Comparison Studies had an ICI group and at least one comparison placebo, chemotherapy, 
or alternative ICI control group 
Outcome Grade 3-4 toxicities per the CTCAE or RTOG guidelines 
Study design All prospective phase III/IV clinical trials 
ICI+RT 
Population Cancer patients undergoing treatment of cancer by ICI+RT 
Intervention Any combination of ICI with RT 
Comparison Studies could have no control group (single-arm study), or could be multi-arm 
studies comparing therapies (e.g. ICI vs ICI+RT, ICI vs tyrosine kinase 
inhibitors) 
Outcome Grade 3-4 toxicities per the CTCAE or RTOG guidelines 
Study design All prospective or retrospective studies with one or more arms 
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 Few studies characterize combined immunotherapy and radiation 
 Toxicities similar after adding radiation to immunotherapy 
 Anti-CTLA4 associated with more toxicity than anti-PD1/PDL1 
 No significant difference based on timing of immunotherapy and radiation 
 
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on August 17, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
